Switch theme
Sign up to access all valuation multiples
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
1997
184
LTM Revenue $83.9M
LTM EBITDA -$14.6M
$368M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NeuroPace has a last 12-month revenue of $83.9M and a last 12-month EBITDA of -$14.6M.
In the most recent fiscal year, NeuroPace achieved revenue of $79.9M and an EBITDA of -$16.6M.
NeuroPace expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NeuroPace valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $65.4M | $79.9M | XXX | XXX | XXX |
| Gross Profit | $32.5M | $48.1M | XXX | XXX | XXX |
| Gross Margin | 50% | 60% | XXX | XXX | XXX |
| EBITDA | -$22.8M | -$16.6M | XXX | XXX | XXX |
| EBITDA Margin | -35% | -21% | XXX | XXX | XXX |
| Net Profit | -$47.1M | -$33.0M | XXX | XXX | XXX |
| Net Margin | -72% | -41% | XXX | XXX | XXX |
| Net Debt | $46.3M | $38.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, NeuroPace's stock price is $11.
NeuroPace has current market cap of $347M, and EV of $368M.
See NeuroPace trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $368M | $347M | XXX | XXX | XXX | XXX | $-0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, NeuroPace has market cap of $347M and EV of $368M.
NeuroPace's trades at 4.4x LTM EV/Revenue multiple, and -25.2x LTM EBITDA.
Analysts estimate NeuroPace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for NeuroPace and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $368M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | -22.2x | XXX | XXX | XXX |
| P/E | -12.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -20.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNeuroPace's NTM/LTM revenue growth is 15%
NeuroPace's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, NeuroPace's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate NeuroPace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for NeuroPace and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -5% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 30% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 101% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeuroPace acquired XXX companies to date.
Last acquisition by NeuroPace was XXXXXXXX, XXXXX XXXXX XXXXXX . NeuroPace acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was NeuroPace founded? | NeuroPace was founded in 1997. |
| Where is NeuroPace headquartered? | NeuroPace is headquartered in United States of America. |
| How many employees does NeuroPace have? | As of today, NeuroPace has 184 employees. |
| Who is the CEO of NeuroPace? | NeuroPace's CEO is Mr. Joel Becker. |
| Is NeuroPace publicy listed? | Yes, NeuroPace is a public company listed on NAS. |
| What is the stock symbol of NeuroPace? | NeuroPace trades under NPCE ticker. |
| When did NeuroPace go public? | NeuroPace went public in 2021. |
| Who are competitors of NeuroPace? | Similar companies to NeuroPace include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of NeuroPace? | NeuroPace's current market cap is $347M |
| What is the current revenue of NeuroPace? | NeuroPace's last 12-month revenue is $83.9M. |
| What is the current EBITDA of NeuroPace? | NeuroPace's last 12-month EBITDA is -$14.6M. |
| What is the current EV/Revenue multiple of NeuroPace? | Current revenue multiple of NeuroPace is 4.4x. |
| What is the current EV/EBITDA multiple of NeuroPace? | Current EBITDA multiple of NeuroPace is -25.2x. |
| What is the current revenue growth of NeuroPace? | NeuroPace revenue growth between 2023 and 2024 was 22%. |
| Is NeuroPace profitable? | Yes, NeuroPace is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
